This brand name is authorized in Australia, Hong Kong, New Zealand
The drug MELIZIDE contains one active pharmaceutical ingredient (API):
|
1
Glipizide
UNII X7WDT95N5C - GLIPIZIDE
|
|
Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BB07 | Glipizide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 2440K |
| Country: HK | Department of Health Drug Office | Identifier(s): 41756 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 6591 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
